Antibodies modulate ongoing and future B cell responses. Cyster and Wilson review the various mechanisms whereby antibody feedback shapes B cell responses and present a framework for conceptualizing the ways antigen-specific antibody may influence immunity in conditions as diverse as infectious disease, autoimmunity, and cancer.
From JAMA: The US Food and Drug Administration recently cleared the Apple Watch hypertension notification feature.
Researchers applied performance metrics reported by Apple to nationally representative survey data and found that, overall, 69% of individuals who receive a smartwatch alert would have hypertension, while 79% of those who do not receive an alert would not have hypertension. However, these rates vary according to subgroup characteristics, such as age and sex.
Current guidelines recommend cuff-based blood pressure measurement as the standard for diagnosing hypertension. Incorporating cuffless device technologies into public health screening efforts will require additional validation and careful attention to device accuracy to reduce misclassification and the risk of false reassurance.
This cross-sectional study assesses the potential impact of a smartwatch hypertension notification feature for US adults who have not been diagnosed with hypertension.
CRISPR-based genome editing therapeutics are entering the clinic, but in vitro and in vivo tools are needed to assess their safety and efficacy. The authors review complementary technologies to monitor the biological effects of genome editing across scales, including the direct measurement of editing outcomes in DNA, human microphysiological systems and non-invasive in vivo imaging.
Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD
Discount Links/Affiliates:
Blood testing (where I get the majority of my labs): https://www.ultalabtests.com/partners/michaellustgarten.
Blood testing with LifeExtension.com: https://www.anrdoezrs.net/click-101614996-15750394
At-Home Metabolomics: https://www.iollo.com?ref=michael-lustgarten.
Use Code: CONQUERAGING At Checkout.
Clearly Filtered Water Filter: https://get.aspr.app/SHoPY
Epigenetic, Telomere Testing: https://trudiagnostic.com/?irclickid=U-s3Ii2r7xyIU-LSYLyQdQ6…M0&irgwc=1
A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this class of drugs work better. The research is published in the journal Science Translational Medicine.
PARP inhibitors are a common treatment for ovarian cancer and can be especially effective in cancers with impaired DNA repair. However, many tumors eventually stop responding, even when the drugs initially show results. The new research identifies a way cancer cells may survive PARP inhibitor treatment early on, and it points to a potential strategy to block that response.
In the study, researchers found that ovarian cancer cells rapidly activate a pro-survival program after exposure to PARP inhibitors. A key driver of this response is FRA1, a transcription factor that helps turn on genes that allow cancer cells to adapt and avoid cell death.
What if we could test spinal cord injury therapies in human tissue without a clinical trial?
It could be possible, as spinal cord organoids derived from human stem cells now replicate real injury responses.
Read more.
Organoids developed from human stem cells modeled spinal cord injuries, providing a powerful in vitro tool to evaluate regenerative therapies for CNS injuries.
Researchers have identified a biological mechanism that helps explain why some lung and ovarian cancers become resistant to chemotherapy, offering insight into why cancers recur. The study, published in Nature Aging this month, investigated how platinum-based chemotherapies such as cisplatin negatively affect tumor behavior in non-small cell lung cancer (NSCLC) and high-grade serous ovarian cancer (HGSOC). Although these treatments are widely used, their long-term effectiveness is often limited when tumors return or stop responding.
Professor Ljiljana Fruk and Muhamad Hartono from the Department of Chemical Engineering and Biotechnology (CEB) contributed to the international collaboration, led by researchers from the Early Cancer Institute and the Cancer Research UK Cambridge Institute. Their involvement follows her Bionano Engineering group’s recent development of a urine test for early lung cancer detection.
In a study published today, Friday, February 13, 2026, in the journal Nature Aging, researchers show that blood-based biomarkers can support accurate dementia diagnosis across diverse populations when integrated with cognitive and neuroimaging measures. Blood-based biomarkers are emerging as one of the most promising advances for the global diagnosis of dementia, including Alzheimer’s disease and frontotemporal lobar degeneration. These tests offer a more accessible, scalable, and cost-effective alternative to traditional diagnostic tools such as brain imaging or cerebrospinal fluid analysis.
However, most blood-based biomarkers have been developed and validated primarily in relatively homogeneous populations. Genetic background, overall physical health, and environmental and social exposures can substantially influence biomarker levels, raising concerns about how well these tests perform across diverse populations worldwide.